The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

All thanks to three key catalysts. Tempus AI just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which includes $375 million in cash payments and $225 million ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark broader industry growth?

Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...

Former House Speaker Nancy Pelosi's stock portfolio has taken a major hit in 2025, aligning with the broader market sell-off.

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit. Northwestern Medicine will be the first system to use Tempus' new algorithm to ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...